Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A |
| ||
| B |
| ||
| C |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dasatinib | Drug | Tablets, Oral, 50 mg, once daily, for one day |
|
|
Inclusion Criteria - All subjects:
Inclusion Criteria - Liver Impaired subjects:
Exclusion Criteria - All subjects:
Not provided
Not provided
Male and Female Subjects with hepatic insufficiency conforming to Child-Pugh classification B
Male and Female Subjects with hepatic insufficiency conforming to Child-Pugh classification C
Healthy Control subjects in good health
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Of Miami | Miami | Florida | 33136 | United States | ||
| Comprehensive Phase One |
Not provided
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| ID | Term |
|---|---|
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069439 | Dasatinib |
| ID | Term |
|---|---|
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole Blood
| Dasatinib | Drug | Tablets, Oral, 20 mg, once daily for one day |
|
|
| Dasatinib | Drug | Tablets, Oral, 70 mg, once daily for one day |
|
|
| Miramar |
| Florida |
| 33025 |
| United States |
| Orlando Clinical Research Center | Orlando | Florida | 32809 | United States |
| New Orleans Center For Clinical Research | Knoxville | Tennessee | 37920 | United States |
| D006573 |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011743 | Pyrimidines |